What We Do     Team     Therapeutic Areas     Partnering     News     Contact

2018

 

2016

 

2015

 

2014

 

2012

 

2011

 

2010

 

2009

 

2008

 

2007

 

moksha8 Expands Alliance with Roche to Commercialize $200 Million of Products in Brazil and Mexico

 

moksha8, Inc. announced today that it has expanded its strategic partnership with Roche to commercialize an additional portfolio of products in Mexico currently generating sales of $140 million USD. moksha8 will commercialize products in three therapeutic areas, CNS disease, anti-infectives, and inflammation. The product portfolio consists of well-known brands including Rivotril®, Rocephin® and Bactrim®

 

“moksha8 has produced strong results for Roche in Brazil and we are delighted to expand our relationship to include Mexico as a key country in Latin America” said Ernest Egli, President of Roche Latin America. “moksha8 brings strong commercial capabilities and innovative marketing to our CNS, anti-infectives and inflammation franchises. We look forward to continuing this valuable relationship.”

 

“moksha8 has established a broad footprint in Latin America with leading products that are cornerstones of medical care,”” said the CEO of moksha8. “We look forward to continuing our strong relationship with Roche and driving value from this important portfolio of products. We are now firmly positioned as the leading partner of choice for pharmaceutical and biotechnology companies looking to generate value across Latin America.”

 

In just over a year, moksha8 has grown its commercial organization to over 200 employees in Brazil and Mexico and a portfolio of products with sales of $200 million USD. moksha8 is uniquely positioned as the leading specialty pharmaceutical company in Latin America with a strong presence in CNS, anti-infectives and inflammation.

 

COPYRIGHT © 2006-2018 MOKSHA8 PHARMACEUTICALS, INC. ALL RIGHTS RESERVED. THIS INFORMATION—INCLUDING PRODUCT INFORMATION—IS INTENDED ONLY FOR RESIDENTS OF THE UNITED STATES. THE PRODUCTS DISCUSSED HEREIN MAY HAVE DIFFERENT LABELING IN DIFFERENT COUNTRIES.